BriaCell Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

BriaCell TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 28.2% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 90.9% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-28.2%

Wachstumsrate der Gewinne

-26.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	90.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

BriaCell stock rises on license deal for anti-cancer agent

Aug 04

BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy

Jul 05

BriaCell, Harvard enter research agreement to identify targets for cancer treatments

Jun 29

BriaCell Therapeutics receives proceed of $12.88M from warrant exercises

Jun 10

BriaCell Therapeutics skyrockets 104% on robust overall survival benefit in advanced breast cancer patients

Jun 02

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BCTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
7/31/2026	N/A	-52	N/A	N/A	1
7/31/2025	N/A	-37	N/A	N/A	1
7/31/2024	N/A	-24	N/A	N/A	1
4/30/2024	N/A	-6	-31	-31	N/A
1/31/2024	N/A	-13	-31	-31	N/A
10/31/2023	N/A	-13	-28	-28	N/A
7/31/2023	N/A	-20	-24	-24	N/A
4/30/2023	N/A	-18	-16	-16	N/A
1/31/2023	N/A	-23	-16	-16	N/A
10/31/2022	N/A	0	-14	-14	N/A
7/31/2022	N/A	-27	-12	-12	N/A
4/30/2022	N/A	-42	-11	-11	N/A
1/31/2022	N/A	-30	-12	-12	N/A
10/31/2021	N/A	-41	-9	-9	N/A
7/31/2021	N/A	-14	-8	-8	N/A
4/30/2021	N/A	2	-6	-6	N/A
1/31/2021	N/A	-2	-1	-1	N/A
10/31/2020	N/A	-3	-1	-1	N/A
7/31/2020	N/A	-4	-1	-1	N/A
4/30/2020	N/A	-4	-1	-1	N/A
1/31/2020	N/A	-5	-3	-3	N/A
10/31/2019	N/A	-5	-4	-4	N/A
8/1/2019	N/A	-5	-4	-4	N/A
4/30/2019	N/A	-5	-4	-4	N/A
1/31/2019	N/A	-5	-4	-4	N/A
10/31/2018	N/A	-4	-4	-4	N/A
7/31/2018	N/A	-4	-4	-4	N/A
4/30/2018	N/A	-3	-3	-3	N/A
1/31/2018	N/A	-3	N/A	-3	N/A
10/31/2017	N/A	-3	N/A	-2	N/A
7/31/2017	N/A	-3	N/A	-2	N/A
4/30/2017	N/A	-2	N/A	-2	N/A
1/31/2017	N/A	-1	N/A	-1	N/A
10/31/2016	N/A	-2	N/A	-1	N/A
7/31/2016	N/A	-2	N/A	-1	N/A
4/30/2016	N/A	-2	N/A	-1	N/A
1/31/2016	N/A	-2	N/A	-1	N/A
10/31/2015	N/A	-3	N/A	-1	N/A
7/31/2015	N/A	-3	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BCTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BCTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BCTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BCTX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: BCTX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BCTX in 3 Jahren voraussichtlich hoch sein wird

BriaCell Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024

BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer

New minor risk - Shareholder dilution

Independent Director recently bought US$2.0m worth of stock

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.80586 million.

BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

New major risk - Negative shareholders equity

BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing

BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset

BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

BriaCell Therapeutics Corp., Annual General Meeting, Jan 30, 2024

BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

New minor risk - Share price stability

New major risk - Financial position

BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt™ in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. completed the Spin-Off of 33.33% stake in Pre-Clinical Assets of BriaCell Therapeutics Corp.

Briacell Receives National Cancer Institute Grant to Advance Its Bria-Ots™ Immunotherapy for Cancer

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

Independent Chairman of the Board recently bought US$118k worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, Jan 24, 2023

BriaCell Therapeutics Corp. Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing

BriaCell Therapeutics Corp. Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Secures License for A Promising Novel Anti-Cancer Agent

BriaCell stock rises on license deal for anti-cancer agent

BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy

BriaCell, Harvard enter research agreement to identify targets for cancer treatments

BriaCell Therapeutics Corp. Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

BriaCell Advances Preparatory Work for New Bria-OTS Breast Cancer Clinical Trial

High number of new directors

BriaCell Therapeutics Corp. Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

BriaCell Therapeutics Corp. Appoints Alexander Kharazi to Its Scientific Advisory Board

Director recently bought US$433k worth of stock

Briacell Therapeutics Corp. Appoints Giuseppe Del Priore as Chief Medical Officer

Director recently bought US$355k worth of stock

BriaCell Therapeutics Corp.(TSXV:BCT) dropped from S&P/TSX Venture Composite Index

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

BriaCell Therapeutics Corp. Announces Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

Investor sentiment improved over the past week

Briacell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell Therapeutics receives proceed of $12.88M from warrant exercises

BriaCell Therapeutics Corp. announced that it has received $27.195924 million in funding

BriaCell Therapeutics Corp. announced that it expects to receive $27.195924 million in funding

Briacell Therapeutics Corp. Provides an Update on the Overall Survival (Os) Data on Its Previously Disclosed Advanced Breast Cancer Patients

BriaCell Therapeutics skyrockets 104% on robust overall survival benefit in advanced breast cancer patients

CEO, President & Director recently bought US$260k worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, May 18, 2021

New 90-day low: US$3.40

BriaCell Therapeutics Corp's Common Shares Deleted from Other OTC

Briacell Presents Clinical Data At the 2020 San Antonio Breast Cancer Symposium®

BriaCell Therapeutics Corp. Appoints Martin Schmieg to Board of Directors

BriaCell Therapeutics Corp. announced that it has received CAD 0.265 million in funding

Briacell Therapeutics Corp. Announces Collaboration with the National Cancer Institute

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken